Suggestions that the U.S. should emulate other countries on drug price controls or patents obscure how our present policies ...

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Reorganizing its generics business strategy to target 60% instead of 80% of drugs coming off patent and reallocating resources to complex generics will help Teva offset base business erosion and ...

In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration ...

But a generic version (and the active ingredient) of this popular medication, sildenafil, is widely available from several drug manufacturers at a fraction of the cost. Read on to find out more ...

The U.S. Food and Drug Administration announced a Class II recall for more than 7,100 bottles of Duloxetine — a generic antidepressant for Cymbalta — due to a cancerous chemical. A voluntary ...

Prior to the end of the year, the company expects an end-of-Phase II meeting with the FDA for its subcutaneous formulation of VK2735, after which it plans to push the drug candidate into late-stage ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic ... of drugs/therapies, particularly ones in late-phase development, as ...

Now Dotmatics, a leader in research and development scientific software, wants to give drug researchers the power ... Geneious Luma is designed to streamline the process of biologic therapeutic ...